Manuel Salto-Tellez

List of Publications by Year
in descending order

123 papers	8,041 citations	109137 35 h-index	58464 82 g-index
127 all docs	127 docs citations	127 times ranked	15375 citing authors

#	Article	IF	Citations
1	QuPath: Open source software for digital pathology image analysis. Scientific Reports, 2017, 7, 16878.	1.6	3,854
2	Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer. Journal of the National Cancer Institute, 2017, 109, djw199.	3.0	338
3	Digital pathology and image analysis in tissue biomarker research. Methods, 2014, 70, 59-73.	1.9	162
4	Reliability of Tissue Microarrays in Detecting Protein Expression and Gene Amplification in Breast Cancer. Modern Pathology, 2003, 16, 79-85.	2.9	161
5	Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. Nature Reviews Clinical Oncology, 2017, 14, 562-576.	12.5	150
6	Identification of a BRCA1-mRNA Splicing Complex Required for Efficient DNA Repair and Maintenance of Genomic Stability. Molecular Cell, 2014, 54, 445-459.	4.5	146
7	Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis. Cancer Discovery, 2021, 11, 1212-1227.	7.7	139
8	Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer. Clinical Cancer Research, 2016, 22, 4095-4104.	3.2	135
9	Artificial intelligenceâ€"the third revolution in pathology. Histopathology, 2019, 74, 372-376.	1.6	107
10	EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer. Clinical Cancer Research, 2016, 22, 230-242.	3.2	97
11	MicroRNA-34c Inversely Couples the Biological Functions of the Runt-related Transcription Factor RUNX2 and the Tumor Suppressor p53 in Osteosarcoma. Journal of Biological Chemistry, 2013, 288, 21307-21319.	1.6	95
12	AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer. Clinical Cancer Research, 2014, 20, 164-175.	3.2	95
13	BRCA1 Deficiency Exacerbates Estrogen-Induced DNA Damage and Genomic Instability. Cancer Research, 2014, 74, 2773-2784.	0.4	94
14	Identification and Validation of an Anthracycline/Cyclophosphamideâ€"Based Chemotherapy Response Assay in Breast Cancer. Journal of the National Cancer Institute, 2014, 106, djt335.	3.0	91
15	Elucidating the molecular physiopathology of acute respiratory distress syndrome in severe acute respiratory syndrome patients. Virus Research, 2009, 145, 260-269.	1.1	85
16	Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancer. Laboratory Investigation, 2018, 98, 15-26.	1.7	81
17	Swarm learning for decentralized artificial intelligence in cancer histopathology. Nature Medicine, 2022, 28, 1232-1239.	15.2	77
18	A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment. Molecular Oncology, 2020, 14, 2384-2402.	2.1	71

#	Article	IF	Citations
19	Nextâ€generation sequencing: a change of paradigm in molecular diagnostic validation. Journal of Pathology, 2014, 234, 5-10.	2.1	68
20	Validation of the systematic scoring of immunohistochemically stained tumour tissue microarrays using QuPath digital image analysis. Histopathology, 2018, 73, 327-338.	1.6	63
21	The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer. Histopathology, 2014, 65, 340-352.	1.6	59
22	Guidelines and considerations for conducting experiments using tissue microarrays. Histopathology, 2013, 62, 827-839.	1.6	57
23	Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP). Gut, 2022, 71, 854-863.	6.1	57
24	Evaluation of PTGS2 Expression, PIK3CA Mutation, Aspirin Use and Colon Cancer Survival in a Population-Based Cohort Study. Clinical and Translational Gastroenterology, 2017, 8, e91.	1.3	56
25	Identifying mismatch repairâ€deficient colon cancer: nearâ€perfect concordance between immunohistochemistry and microsatellite instability testing in a large, populationâ€based series. Histopathology, 2021, 78, 401-413.	1.6	55
26	Recommendations for determining HPV status in patients with oropharyngeal cancers under TNM8 guidelines: a two-tier approach. British Journal of Cancer, 2019, 120, 827-833.	2.9	51
27	Digital pathology and artificial intelligence will be key to supporting clinical and academic cellular pathology through COVID-19 and future crises: the PathLAKE consortium perspective. Journal of Clinical Pathology, 2021, 74, 443-447.	1.0	49
28	QuPath: The global impact of an open source digital pathology system. Computational and Structural Biotechnology Journal, 2021, 19, 852-859.	1.9	49
29	Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia. British Journal of Cancer, 2020, 123, 1280-1288.	2.9	45
30	Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer. Journal of Oncology, 2018, 2018, 1-14.	0.6	44
31	Automated tumor analysis for molecular profiling in lung cancer. Oncotarget, 2015, 6, 27938-27952.	0.8	43
32	Critical Appraisal of Programmed Death Ligand 1 Reflex Diagnostic Testing: Current Standards and Future Opportunities. Journal of Thoracic Oncology, 2019, 14, 45-53.	0.5	42
33	RNAscope in situ hybridization confirms mRNA integrity in formalin-fixed, paraffin-embedded cancer tissue samples. Oncotarget, 2017, 8, 93392-93403.	0.8	41
34	Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility. Oncotarget, 2015, 6, 20863-20874.	0.8	41
35	Immunohistochemistry in the era of personalised medicine. Journal of Clinical Pathology, 2013, 66, 58-61.	1.0	40
36	BCL-2 system analysis identifies high-risk colorectal cancer patients. Gut, 2017, 66, 2141-2148.	6.1	40

#	Article	IF	Citations
37	Quantification of HER2 heterogeneity in breast cancerâ€“implications for identification of sub-dominant clones for personalised treatment. Scientific Reports, 2016, 6, 23383.	1.6	38
38	Tissue-based next generation sequencing: application in a universal healthcare system. British Journal of Cancer, 2017, 116, 553-560.	2.9	38
39	Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. British Journal of Cancer, 2017, 117, 203-209.	2.9	38
40	Immunohistochemistry should undergo robust validation equivalent to that of molecular diagnostics. Journal of Clinical Pathology, 2015, 68, 766-770.	1.0	37
41	Statin use, candidate mevalonate pathway biomarkers, and colon cancer survival in a population-based cohort study. British Journal of Cancer, 2017, 116, 1652-1659.	2.9	37
42	Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer. Journal of Translational Medicine, 2015, 13, 217.	1.8	36
43	Diagnosis of digestive system tumours. International Journal of Cancer, 2021, 148, 1040-1050.	2.3	36
44	Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy. Cancer Immunology Research, 2016, 4, 582-591.	1.6	35
45	Sphingosine Kinase 1 Promotes Malignant Progression in Colon Cancer and Independently Predicts Survival of Patients With Colon Cancer by Competing Risk Approach in South Asian Population. Clinical and Translational Gastroenterology, 2014, 5, e51.	1.3	34
46	Improving the Diagnostic Accuracy of the PD-L1 Test with Image Analysis and Multiplex Hybridization. Cancers, 2020, 12, 1114.	1.7	34
47	PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy. Oncotarget, 2016, 7, 7885-7898.	0.8	33
48	Molecular pathology â€“ The value of an integrative approach. Molecular Oncology, 2014, 8, 1163-1168.	2.1	32
49	Building a â€˜Repository of Scienceâ€™: The importance ofÂintegrating biobanks within molecular pathology programmes. European Journal of Cancer, 2016, 67, 191-199.	1.3	31
50	Invited reviewâ€”next-generation sequencing: a modern tool in cytopathology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 3-11.	1.4	31
51	Analysis of wntless (WLS) expression in gastric, ovarian, and breast cancers reveals a strong association with HER2 overexpression. Modern Pathology, 2015, 28, 428-436.	2.9	27
52	More Than a Decade of Molecular Diagnostic Cytopathology Leading Diagnostic and Therapeutic Decision-Making. Archives of Pathology and Laboratory Medicine, 2018, 142, 443-445.	1.2	26
53	Gastrointestinal tissueâ€based molecular biomarkers: a practical categorisation based on the 2019 World Health Organization classification of epithelial digestive tumours. Histopathology, 2020, 77, 340-350.	1.6	26
54	Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival. Modern Pathology, 2017, 30, 1287-1298.	2.9	23

#	Article	IF	Citations
55	A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer. Clinical Cancer Research, 2017, 23, 1200-1212.	3.2	21
56	Time for change: a new training programme for morpho-molecular pathologists?. Journal of Clinical Pathology, 2018, 71, 285-290.	1.0	21
57	The clinical and molecular significance associated with STING signaling in breast cancer. Npj Breast Cancer, 2021, 7, 81.	2.3	21
58	A gene signature associated with PTEN activation defines good prognosis intermediate risk prostate cancer cases. Journal of Pathology: Clinical Research, 2018, 4, 103-113.	1.3	20
59	The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation. BMC Cancer, 2020, 20, 500.	1.1	20
60	Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma. Gut, 2019, 68, 1918-1927.	6.1	18
61	PTEN mRNA detection by chromogenic, RNA in situ technologies: a reliable alternative to PTEN immunohistochemistry. Human Pathology, 2016, 47, 95-103.	1.1	17
62	Defining the molecular evolution of extrauterine high grade serous carcinoma. Gynecologic Oncology, 2019, 155, 305-317.	0.6	17
63	A Means of Assessing Deep Learning-Based Detection of ICOS Protein Expression in Colon Cancer. Cancers, 2021, 13, 3825.	1.7	17
64	Standardising RNA profiling based biomarker application in cancerâ€"The need for robust control of technical variables. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 258-272.	3.3	16
65	Morphomolecular pathology: setting the framework for a new generation of pathologists. British Journal of Cancer, 2017, 117, 1581-1582.	2.9	16
66	Alcohol intake, tobacco smoking, and esophageal adenocarcinoma survival: a molecular pathology epidemiology cohort study. Cancer Causes and Control, 2020, 31, 1-11.	0.8	16
67	Molecular Pathology in Contemporary Diagnostic Pathology Laboratory. American Journal of Surgical Pathology, 2010, 34, 115-117.	2.1	15
68	PICan: An integromics framework for dynamic cancer biomarker discovery. Molecular Oncology, 2015, 9, 1234-1240.	2.1	15
69	Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer. Oncotarget, 2016, 7, 36632-36644.	0.8	15
70	Validation of immunocytochemistry as a morphomolecular technique. Cancer Cytopathology, 2016, 124, 540-545.	1.4	14
71	HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee. Journal of Clinical Pathology, 2018, 71, 388-394.	1.0	14
72	Comparison of Molecular Assays for HPV Testing in Oropharyngeal Squamous Cell Carcinomas: A Population-Based Study in Northern Ireland. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 31-38.	1.1	14

#	Article	IF	Citations
73	The prognostic value of the stem-like group in colorectal cancer using a panel of immunohistochemistry markers. Oncotarget, 2015, 6, 12763-12773.	0.8	14
74	In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer. Clinical Cancer Research, 2021, 27, 288-300.	3.2	13
75	Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinoma. Oncotarget, 2018, 9, 18518-18528.	0.8	13
76	Gelsolin-mediated activation of PI3K/Akt pathway is crucial for hepatocyte growth factor-induced cell scattering in gastric carcinoma. Oncotarget, 2016, 7, 25391-25407.	0.8	13
77	samExploreR: exploring reproducibility and robustness of RNA-seq results based on SAM files. Bioinformatics, 2016, 32, 3345-3347.	1.8	11
78	PD-L1 Multiplex and Quantitative Image Analysis for Molecular Diagnostics. Cancers, 2021, 13, 29.	1.7	11
79	Training and accreditation standards for pathologists undertaking clinical trial work. Journal of Pathology: Clinical Research, 2019, 5, 100-107.	1.3	10
80	Cancer taxonomy: pathology beyond pathology. European Journal of Cancer, 2019, 115, 57-60.	1.3	10
81	Evolutionary genetic algorithm identifies IL2RB as a potential predictive biomarker for immune-checkpoint therapy in colorectal cancer. NAR Genomics and Bioinformatics, 2021, 3, lqab016.	1.5	10
82	Lowâ€contact and highâ€interconnectivity pathology (LC&HI Path): postâ€COVID19â€pandemic practice of pathology. Histopathology, 2020, 77, 518-524.	1.6	9
83	GLOBAL BALLAD: An International Rare Cancers Initiative trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma (IRCI 002).. Journal of Clinical Oncology, 2016, 34, TPS4154-TPS4154.	0.8	9
84	p16 as a prognostic indicator in ovarian/tubal highâ€grade serous carcinoma. Histopathology, 2016, 68, 615-618.	1.6	8
85	Rare cancers: the greatest inequality in cancer research and oncology treatment. British Journal of Cancer, 2017, 117, 1255-1257.	2.9	8
86	Systematic evaluation of PAXgeneÂ® tissue fixation for the histopathological and molecular study of lung cancer. Journal of Pathology: Clinical Research, 2020, 6, 40-54.	1.3	8
87	Colonic epithelial cathelicidin (<scp>LL</scp>â€37) expression intensity is associated with progression of colorectal cancer and presence of <scp>CD8</scp>⁺ T cell infiltrate. Journal of Pathology: Clinical Research, 2021, 7, 495-506.	1.3	8
88	Molecular classification of non-invasive breast lesions for personalised therapy and chemoprevention. Oncotarget, 2015, 6, 43244-43254.	0.8	8
89	Potential quality pitfalls of digitalized whole slide image of breast pathology in routine practice. Modern Pathology, 2022, 35, 903-910.	2.9	8
90	Practical guide for the comparison of two next-generation sequencing systems for solid tumour analysis in a universal healthcare system. Journal of Clinical Pathology, 2019, 72, 225-231.	1.0	7

#	Article	IF	Citations
91	Vitamin D receptor as a marker of prognosis in oesophageal adenocarcinoma: a prospective cohort study. Oncotarget, 2018, 9, 34347-34356.	0.8	7
92	Integrated molecular pathology: the Belfast model. Drug Discovery Today, 2015, 20, 1451-1454.	3.2	6
93	More Than a Decade of Molecular Diagnostic Cytopathology Leading Diagnostic and Therapeutic Decision-Making. Archives of Pathology and Laboratory Medicine, 2018, , .	1.2	6
94	Sex hormone receptor expression and survival in esophageal adenocarcinoma: a prospective cohort study. Oncotarget, 2018, 9, 35300-35312.	0.8	6
95	Delivering a researchâ€enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program. Cancer, 2016, 122, 664-673.	2.0	5
96	HistoClean: Open-source software for histological image pre-processing and augmentation to improve development of robust convolutional neural networks. Computational and Structural Biotechnology Journal, 2021, 19, 4840-4853.	1.9	5
97	General Roadmap and Core Steps for the Development of AI Tools in Digital Pathology. Diagnostics, 2022, 12, 1272.	1.3	4
98	Impact of Variable RNA-Sequencing Depth on Gene Expression Signatures and Target Compound Robustness: Case Study Examining Brain Tumor (Glioma) Disease Progression. JCO Precision Oncology, 2018, 2, 1-17.	1.5	3
99	Orthogonal MET analysis in a populationâ€representative stage IIâ€“III colon cancer cohort: prognostic and potential therapeutic implications. Molecular Oncology, 2021, 15, 3317-3328.	2.1	3
100	Association of a DNA damage response deficiency (DDRD) assay and prognosis in early-stage esophageal adenocarcinoma.. Journal of Clinical Oncology, 2014, 32, 4015-4015.	0.8	3
101	MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.. Journal of Clinical Oncology, 2015, 33, TPS3632-TPS3632.	0.8	3
102	EORTC-1203: Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive stomach cancerâ€"INNOVATION trial.. Journal of Clinical Oncology, 2016, 34, TPS4133-TPS4133.	0.8	2
103	NUQA: Estimating Cancer Spatial and Temporal Heterogeneity and Evolution through Alignment-Free Methods. Molecular Biology and Evolution, 2019, 36, 2883-2889.	3.5	1
104	High PTGS2 expression in postâ€neoadjuvant chemotherapyâ€treated oesophageal adenocarcinoma is associated with improved survival: a populationâ€based cohort study. Histopathology, 2019, 74, 587-596.	1.6	1
105	Abstract 2079: EpHA2 is an essential driver of invasion and a novel target in KRAS mutant colorectal cancer. , 2014, , .		1
106	Abstract 4018: The role of c-MET/HGF signaling as a critical mediator of an invasive and resistant phenotype in colorectal cancer. , 2015, , .		1
107	A systems model of BCL-2 dependent apoptosis to predict stage II CRC patients benefiting from adjuvant chemotherapy and as a prognostic tool for stage III CRC patients with increased risk of recurrence.. Journal of Clinical Oncology, 2016, 34, 3584-3584.	0.8	1
108	PD-L1 expression and response to neo-adjuvant chemotherapy in esophageal adenocarcinoma.. Journal of Clinical Oncology, 2017, 35, 4023-4023.	0.8	1

#	Article	IF	Citations
109	Identification of a prognostic signature in colorectal cancer using combinatorial algorithmâ€driven analysis. Journal of Pathology: Clinical Research, 2022, , .	1.3	1
110	RE: Test of Four Colon Cancer Risk-Scores in Formalin Fixed Paraffin Embedded Microarray Gene Expression Data. Journal of the National Cancer Institute, 2015, 107, djv055-djv055.	3.0	0
111	Identification and validation of an assay predictive of response and prognosis following anthracycline-based chemotherapy for early breast cancer.. Journal of Clinical Oncology, 2013, 31, TPS11120-TPS11120.	0.8	0
112	The prognostic and therapeutic value of EpHA2 in early colorectal cancer (CRC).. Journal of Clinical Oncology, 2014, 32, 3581-3581.	0.8	0
113	Abstract 1905: Defining a therapeutic classification of breast cancer by actionable targets. , 2014, , .		0
114	Molecular classification of the invasive front in colorectal cancer.. Journal of Clinical Oncology, 2015, 33, 3573-3573.	0.8	0
115	Abstract 4792: Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with clinical utility. , 2015, , .		0
116	Caspase modelling to predict personalised risk in stage III colorectal cancer (CRC) patients.. Journal of Clinical Oncology, 2016, 34, 11592-11592.	0.8	0
117	Abstract 1555: A gene signature associated with PTEN activation defines good outcomes in intermediate-risk prostate cancer cases. , 2018, , .		0
118	Abstract 4049: Assessment of immune biomarkers by digital pathological analysis across a large colorectal cancer patient cohort predicts patient outcome and may provide a clinically relevant therapeutic index for immunotherapeutic treatment stratification. , 2018, , .		0
119	Abstract 3142: Tumor-infiltrating lymphocytes and CD4/FOXP3 ratios reliably predict survival using digital image analysis. , 2018, , .		0
120	Abstract B035: Radio-resistance of PTEN-deficient prostate tumors is enhanced by treatment-induced chemokine signaling and is associated with biochemical recurrence and development of metastasis. , 2018, , .		0
121	A digital pathology demonstration of an "immune hot" ICOS+/CD45RO+ immunephenotype and the impact on survival in patients with esophageal adenocarcinoma.. Journal of Clinical Oncology, 2019, 37, 4062-4062.	0.8	0
122	Abstract LB-088: Exploratory multiplex tissue image analysis of the impact of heterogeneity in the microenvironment of primary colorectal cancer on apoptosis markers in patients. , 2019, , .		0
123	Abstract 2787: Artificial intelligence approach identifies IL2RB as a common prognostic and potential predictive biomarker associated with immune checkpoints in colorectal cancer. , 2019, , .		0